[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1995023225A3 - Procede et reactif inhibiteur de l'expression de genes concernant une affection - Google Patents

Procede et reactif inhibiteur de l'expression de genes concernant une affection Download PDF

Info

Publication number
WO1995023225A3
WO1995023225A3 PCT/IB1995/000156 IB9500156W WO9523225A3 WO 1995023225 A3 WO1995023225 A3 WO 1995023225A3 IB 9500156 W IB9500156 W IB 9500156W WO 9523225 A3 WO9523225 A3 WO 9523225A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrna
enzymatic
complex
nucleic acid
nucleic acids
Prior art date
Application number
PCT/IB1995/000156
Other languages
English (en)
Other versions
WO1995023225A2 (fr
Inventor
Dan T Stinchcomb
Bharat Chowrira
Anthony Direnzo
Kenneth G Draper
Lech W Dudycz
Susan Grimm
Alexander Karpeisky
Kevin Kisich
Jasenka Matulic-Adamic
James A Mcswiggen
Anil Modak
Pamela Pavco
Leonid Beigelman
Sean M Sullivan
David Sweedler
James D Thompson
Danuta Tracz
Nassim Usman
Francine E Wincott
Tod Woolf
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/218,934 external-priority patent/US5639647A/en
Priority claimed from US08/291,932 external-priority patent/US5658780A/en
Priority claimed from US08/292,620 external-priority patent/US5837542A/en
Priority claimed from US08/311,486 external-priority patent/US5811300A/en
Priority claimed from US08/319,492 external-priority patent/US5616488A/en
Priority claimed from US08/321,993 external-priority patent/US5631359A/en
Priority claimed from US08/334,847 external-priority patent/US5693532A/en
Priority claimed from US08/337,608 external-priority patent/US5902880A/en
Priority claimed from US08/357,577 external-priority patent/US5783425A/en
Priority claimed from US08/363,233 external-priority patent/US5714383A/en
Priority to AU18214/95A priority Critical patent/AU706417B2/en
Priority to MX9603638A priority patent/MX9603638A/es
Priority to JP7522236A priority patent/JPH09509323A/ja
Priority to EP95909920A priority patent/EP0746614A1/fr
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Publication of WO1995023225A2 publication Critical patent/WO1995023225A2/fr
Publication of WO1995023225A3 publication Critical patent/WO1995023225A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
    • C12N2310/1241—Tetrahymena
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3523—Allyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des molécules d'ARN enzymatiques clivant les ARNm ICAM-1, IL-5, rel A, TNF-α, RSV, l'ARN génomique RSV ou l'ARNm associé du CML, ainsi que l'utilisation de ces molécules pour le traitement des états pathologiques imputables à ces niveaux de l'ARNm. L'invention concerne également: des ribonucléosides ou des nucléotides modifiés en 2', 3' ou 5' ainsi que les procédés de synthèse, de purification et de déprotection correspondants; des vecteurs contenant des acides nucléiques enzymatiques multiples, éventuellement associés à des ARNt sous des formes chimériques; un procédé d'introduction des acides nucléiques enzymatiques dans des cellules par constitution d'un complexe avec un second acide nucléique, ledit complexe étant capable de prendre une structure en paires de base bouclée en R; un procédé de modification in vivo d'un acide nucléique mutant par hybridation avec un oligonucléotide capable d'activer la désaminase de l'ARNds à activité enzymatique ou chimiquement mutagène. L'invention concerne enfin des ribozymes en épingle à cheveux transclivants ou transligants auxquels manque une moitié d'ARN substratique, ainsi que des ribozymes en tête de marteau à interconnexions en boucle entre les paires de base de la souche II.
PCT/IB1995/000156 1994-02-23 1995-02-23 Procede et reactif inhibiteur de l'expression de genes concernant une affection WO1995023225A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95909920A EP0746614A1 (fr) 1994-02-23 1995-02-23 Procede et reactif inhibiteur de l'expression de genes concernant une affection
JP7522236A JPH09509323A (ja) 1994-02-23 1995-02-23 疾患関連遺伝子の発現を阻害するための方法および試薬
MX9603638A MX9603638A (es) 1994-02-23 1995-02-23 Metodo y reactivo para la inhibicion de la expresion de genes relacionados con enfermedad.
AU18214/95A AU706417B2 (en) 1994-02-23 1995-02-23 Method and reagent for inhibiting the expression of disease related genes

Applications Claiming Priority (52)

Application Number Priority Date Filing Date Title
US20110994A 1994-02-23 1994-02-23
US08/201,109 1994-02-23
US08/218,934 1994-03-29
US08/218,934 US5639647A (en) 1994-03-29 1994-03-29 2'-deoxy-2'alkylnucleotide containing nucleic acid
US22279594A 1994-04-04 1994-04-04
US08/222,795 1994-04-04
US22448394A 1994-04-07 1994-04-07
US08/224,483 1994-04-07
US22795894A 1994-04-15 1994-04-15
US22804194A 1994-04-15 1994-04-15
US08/228,041 1994-04-15
US08/227,958 1994-04-15
US24573694A 1994-05-18 1994-05-18
US08/245,736 1994-05-18
US27128094A 1994-07-06 1994-07-06
US08/271,280 1994-07-06
US08/291,932 US5658780A (en) 1992-12-07 1994-08-15 Rel a targeted ribozymes
US08/291,932 1994-08-15
US29143394A 1994-08-16 1994-08-16
US08/291,433 1994-08-16
US08/292,620 US5837542A (en) 1992-12-07 1994-08-17 Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US08/292,620 1994-08-17
US29352094A 1994-08-19 1994-08-19
US08/293,520 1994-08-19
US30000094A 1994-09-02 1994-09-02
US08/300,000 1994-09-02
US30303994A 1994-09-08 1994-09-08
US08/303,039 1994-09-08
US31174994A 1994-09-23 1994-09-23
US08/311,486 US5811300A (en) 1992-12-07 1994-09-23 TNF-α ribozymes
US08/311,486 1994-09-23
US08/311,749 1994-09-23
US31439794A 1994-09-28 1994-09-28
US08/314,397 1994-09-28
US31677194A 1994-10-03 1994-10-03
US08/316,771 1994-10-03
US08/319,492 1994-10-07
US08/319,492 US5616488A (en) 1992-12-07 1994-10-07 IL-5 targeted ribozymes
US08/321,993 1994-10-11
US08/321,993 US5631359A (en) 1994-10-11 1994-10-11 Hairpin ribozymes
US08/334,847 1994-11-04
US08/334,847 US5693532A (en) 1994-11-04 1994-11-04 Respiratory syncytial virus ribozymes
US08/337,608 1994-11-10
US08/337,608 US5902880A (en) 1994-08-19 1994-11-10 RNA polymerase III-based expression of therapeutic RNAs
US34551694A 1994-11-28 1994-11-28
US08/357,577 US5783425A (en) 1993-10-27 1994-12-16 Amino and peptido modified enzymatic nucleic acid
US08/357,577 1994-12-16
US08/363,233 US5714383A (en) 1992-05-14 1994-12-23 Method and reagent for treating chronic myelogenous leukemia
US08/363,233 1994-12-23
US38073495A 1995-01-30 1995-01-30
US08/345,516 1995-01-30
US08/380,734 1995-01-30

Publications (2)

Publication Number Publication Date
WO1995023225A2 WO1995023225A2 (fr) 1995-08-31
WO1995023225A3 true WO1995023225A3 (fr) 1996-02-01

Family

ID=27586798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/000156 WO1995023225A2 (fr) 1994-02-23 1995-02-23 Procede et reactif inhibiteur de l'expression de genes concernant une affection

Country Status (4)

Country Link
EP (1) EP0746614A1 (fr)
AU (1) AU706417B2 (fr)
CA (1) CA2183992A1 (fr)
WO (1) WO1995023225A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US7538095B2 (en) 1997-12-23 2009-05-26 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002595A1 (fr) * 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Procede et reactif pour le traitement de maladies chez les animaux
CA2176035A1 (fr) 1993-11-08 1995-05-18 Nassim Usman Acide nucleique enzymatique a modification de base
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
CA2207593A1 (fr) * 1994-12-13 1996-06-20 John Gustofson Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes
US5672501A (en) * 1994-12-23 1997-09-30 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
AU4961996A (en) * 1994-12-14 1996-07-03 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
AU712779C (en) 1995-10-19 2002-02-07 Proligo Llc Method for solution phase synthesis of oligonucleotides
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6159951A (en) * 1997-02-13 2000-12-12 Ribozyme Pharmaceuticals Inc. 2'-O-amino-containing nucleoside analogs and polynucleotides
CA2288640A1 (fr) * 1997-05-09 1998-11-12 Ribozyme Pharmaceuticals, Inc. Traitement a l'acide nucleique enzymatique de maladies et etats pathologiques associes aux niveaux d'expression de c-raf
US6548657B1 (en) 1997-06-09 2003-04-15 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6280936B1 (en) 1997-06-09 2001-08-28 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6183959B1 (en) 1997-07-03 2001-02-06 Ribozyme Pharmaceuticals, Inc. Method for target site selection and discovery
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
US6127535A (en) 1997-11-05 2000-10-03 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
ES2374290T3 (es) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation Genes sintéticos y constructos genéticos que comprenden los mismos.
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BR9912672A (pt) 1998-08-18 2002-06-11 Univ California Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6069008A (en) * 1998-11-25 2000-05-30 Isis Pharmaceuticals Inc. Antisense modulation of NF-kappa-B p65 subunit expression
NL1010917C2 (nl) * 1998-12-30 2000-07-03 Stichting Dienst Landbouwkundi DNA-oligonucleotide dat specifiek is voor Meloidogyne-soorten, DNA-vector en gastheercel die het oligonucleotide bevatten, toepassing en kit.
WO2000044914A1 (fr) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
WO2001047530A1 (fr) * 1999-12-28 2001-07-05 Murdoch Childrens Research Institute Procede de therapie et de prophylaxie de l'inflammation
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
EP1229134A3 (fr) 2001-01-31 2004-01-28 Nucleonics, Inc Utilisation de l'inhibition post-transcriptionnelle pour l'identification des séquences d'acides nucléiques qui modifient la fonction d'une cellule
US7115726B2 (en) 2001-03-30 2006-10-03 Perlegen Sciences, Inc. Haplotype structures of chromosome 21
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
EP1386004A4 (fr) 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
EP1465634B1 (fr) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Procedes d'utilisation d'inhibiteurs de recepteur de l'adenosine aux fins d'amelioration de reponse immune et d'inflammation
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
CA2557426A1 (fr) 2004-02-24 2005-10-06 Thomas W. Hodge Rab9a, rab11a et leurs modulateurs lies a une maladie infectieuse
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
AU2005230684B2 (en) 2004-04-05 2011-10-06 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
CA2594334A1 (fr) * 2005-01-07 2006-07-13 Alnylam Pharmaceuticals, Inc. Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation
WO2007137163A2 (fr) 2006-05-19 2007-11-29 Georgia Tech Research Corporation Ligand des transporteurs abc
WO2008008873A2 (fr) 2006-07-14 2008-01-17 Georgia Tech Research Corporation Ligand du canal clc
EP2121921A4 (fr) * 2006-12-13 2010-08-04 Idiverse Inc Nouveaux gènes et molécules d'arn qui confèrent une tolérance à la contrainte
KR20150139582A (ko) 2013-04-04 2015-12-11 조지아 스테이트 유니버시티 리서치 파운데이션, 인크. 나노파티클-지원 신호 증폭을 이용한 rna 마이크로칩 검출
WO2016011381A1 (fr) 2014-07-18 2016-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diminution de l'expression et/ou de la fonction de cxcr4 pour améliorer la prise de greffe de cellules souches hématopoïétiques
WO2016025629A1 (fr) 2014-08-12 2016-02-18 The Regents Of The University Of California Composition moléculaire permettant d'améliorer et de renouveler l'entretien et la réparation des tissus de mammifère
NZ738184A (en) 2015-05-18 2019-09-27 Univ California Methods and compositions for treating aging-associated impairments
WO2021158789A1 (fr) * 2020-02-07 2021-08-12 Ultragenyx Pharmaceutical Inc. Agents chaotropiques pour réduire la formation d'arn double brin
CN111851128A (zh) * 2020-07-28 2020-10-30 太和县昌达工贸有限公司 一种透气均匀抗脏污无纺布网带及其制备方法
CN114544821B (zh) * 2020-11-24 2023-10-24 重庆医科大学 检测血浆中磷脂酰乙醇胺（36:4）的试剂在制备抑郁症检测试剂盒中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007065A1 (fr) * 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ribozymes modifies
WO1994002595A1 (fr) * 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Procede et reactif pour le traitement de maladies chez les animaux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007065A1 (fr) * 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ribozymes modifies
WO1994002595A1 (fr) * 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Procede et reactif pour le traitement de maladies chez les animaux

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BALLANTYNE, C. ET AL.: "Nucleotide sequence of the cDNA for murine intercellular adhesion molecule-1 (ICAM-1)", NUCLEIC ACIDS RESEARCH, vol. 17, no. 14, OXFORD GB, pages 5853 *
BARINAGA, M.: "ribozymes: killing the messenger", SCIENCE, vol. 262, 3 December 1993 (1993-12-03), LANCASTER, PA US, pages 1512 - 1514 *
COTTEN, M.: "THE IN VIVO APPLICATION OF RIBOZYMES", TRENDS IN BIOTECHNOLOGY, vol. 8, no. 7, 1 July 1990 (1990-07-01), pages 174 - 178, XP000133091 *
EDGINGTON, S.M.: "Ribozymes: stop making sense", BIOTECHNOLOGY, vol. 10, NEW YORK US, pages 256 - 262 *
KITA, Y. ET AL.: "Sequence and expression of rat ICAM-1", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1131, pages 108 - 110 *
SIMMONS, D. ET AL.: "ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM", NATURE, vol. 331, 18 February 1988 (1988-02-18), LONDON GB, pages 624 - 627 *
USMAN, N. & CEDERGREN, R.: "Exploiting the chemical synthesis of RNA", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 17, CAMBRIDGE GB, pages 334 - 339 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US7538095B2 (en) 1997-12-23 2009-05-26 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA

Also Published As

Publication number Publication date
WO1995023225A2 (fr) 1995-08-31
EP0746614A1 (fr) 1996-12-11
CA2183992A1 (fr) 1995-08-31
AU706417B2 (en) 1998-06-17
AU1821495A (en) 1995-06-01

Similar Documents

Publication Publication Date Title
WO1995023225A3 (fr) Procede et reactif inhibiteur de l'expression de genes concernant une affection
Svoboda et al. Effect of sequence, adduct type, and opposing lesions on the binding and repair of ultraviolet photodamage by DNA photolyase and (A) BC excinuclease
Hill Jr et al. The limits of template-directed synthesis with nucleoside-5′-phosphoro (2-methyl) imidazolides
Duarte et al. Insertion of dGMP and dAMP during in vitro DNA synthesis opposite an oxidized form of 7, 8-dihydro-8-oxoguanine
US6232462B1 (en) Reduction of nonspecific hybridization by using novel base-pairing schemes
EP2267139A3 (fr) Procédés ét moyens d'obtention de phénotypes modifies
US5573913A (en) 3'-RNA labelling with terminal transferase
EP0348458A4 (en) Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
WO1999055857A3 (fr) Nucleoside triphosphates et leur integration aux ribozymes
Khan et al. A novel method to stabilise antisense oligonucleotides against exonuclease degradation
AU3471293A (en) Enzymatic RNA molecules
DE69625920D1 (de) Expressionsnachweis durch hybridisierung an oligonukleotidarrays hoher belegungsdichte
AU2002352108A8 (en) Nucleic acid linkers and use thereof in gene synthesis
Prakash et al. 2 ‘-O-[2-(Guanidinium) ethyl]-modified oligonucleotides: stabilizing effect on duplex and triplex structures
CA2151801A1 (fr) Derives d'oligonucleotides modifies en 3'
CA2482440A1 (fr) Composes oligomeres a groupes phosphate modifies
Hatahet et al. A novel method for site specific introduction of single model oxidative DNA lesions into oligodeoxyribonucleotides
Nashimoto Anomalous RNA substrates for mammalian tRNA 3′ processing endoribonuclease
MX9603638A (es) Metodo y reactivo para la inhibicion de la expresion de genes relacionados con enfermedad.
WO2002048405A3 (fr) Methode non invasive de detection d'un arn cible
WO1994012518A3 (fr) Reactif pour le couplage de diverses substances a des acides nucleiques et procede pour sa preparation
WO1999027135A3 (fr) Procede d'identification et d'inhibition de molecules fonctionnelles d'acide nucleique dans des cellules
Petyuk et al. Invasion of strongly binding oligonucleotides into tRNA structure
Sugimoto et al. Development of a short Ca2+-dependent deoxyribozyme with RNA cleavage activity
Rabussay et al. Construction and properties of a cell-free system for bacteriophage T4 late RNA synthesis.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2183992

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995909920

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995909920

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995909920

Country of ref document: EP